Rentschler Biopharma SE
Rentschler Biopharma Extends Collaboration with Genmab to U.S. facility
DGAP-News: Rentschler Biopharma SE
/ Key word(s): Statement
– Innovative agreement provides flexible model to address Genmab’s development and manufacturing needs as programs advance in development – Rentschler Biopharma’s U.S. site expansion progressing on track with plans to significantly increase square footage and number of employees Laupheim, Germany and Milford, MA, USA, May 27, 2020 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that the company has entered into a strategic collaboration with Genmab for the process development and manufacture of bispecific antibodies generated with Genmab’s DuoBody(R) technology platform. This partnership uses an innovative business model which fits well with the expansion plans for Rentschler Biopharma’s U.S. site in Milford, MA. Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, said: “We are excited to expand our strategic partnership with Genmab, a leading biotech specializing in the creation and development of differentiated antibody therapeutics, to our U.S. facility. In this new age of personalized medicine, breakthrough molecules, and complex therapies, Rentschler Biopharma welcomes the opportunity to use innovation to empower our clients and ultimately help patients. The work we will do for Genmab at our U.S. site represents a first-of-its-kind collaboration that will involve several novel projects and enable the client to decide in a flexible and agile way which projects to advance and when.” U.S. site expansion making good progress “We are grateful for the trust that Genmab has put in us based on our work for them at our Laupheim site. This extended collaboration with Genmab at our U.S. innovation hub is a perfect fit with our expansion. Our growth will enable us to support our partner at each step of the way as their plans advance and evolve,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “Since acquiring the U.S site in 2019, we have accomplished a lot and are very pleased our expansion is moving forward as planned and on time. We look forward to bringing in additional innovative projects from both new and existing clients.” Contact: Media inquiries:
27.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |